Numorphan
Generalized Anxiety Disorder, Dyspnea, Pain + 3 more
Treatment
20 Active Studies for Numorphan
Treatment for
Generalized Anxiety Disorder
What is Numorphan
Oxymorphone
The Generic name of this drug
Treatment Summary
Pentazocine is a painkiller similar to morphine, but does not have the same effect on coughing. It is used to treat moderate to severe pain, including pain during childbirth. It can also be used in combination with anesthesia. In 2017, the FDA asked Endo Pharmaceuticals to remove this drug from the market due to potential misuse and abuse of the injectable form of the drug.
Numorphan
is the brand name
Numorphan Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Numorphan
Oxymorphone
1959
118
Effectiveness
How Numorphan Affects Patients
Oxymorphone is a type of drug similar to morphine that helps reduce pain. It works by affecting the brain and digestive system, and can also cause drowsiness. Oxymorphone can cause slowed breathing by decreasing the responsiveness of certain parts of the brain responsible for controlling breath.
How Numorphan works in the body
Oxymorphone primarily affects the opioid mu-receptor. This receptor is located in many parts of the brain, including the amygdalae, hypothalamus, thalamus, and cortex. Oxymorphone also binds to and blocks GABA inhibitory neurons, which are responsible for pain regulation. By blocking these neurons, oxymorphone helps reduce pain signals in the body.
When to interrupt dosage
The proposed dosage of Numorphan is contingent upon the diagnosed condition, including Dyspnea, obstetrical analgesia therapy and Perioperative analgesia. The dose is contingent upon the method of administration, as specified in the table below.
Condition
Dosage
Administration
Generalized Anxiety Disorder
, 5.0 mg, 10.0 mg, 20.0 mg, 40.0 mg, 7.5 mg, 15.0 mg, 30.0 mg, 1.0 mg/mL, 1.5 mg/mL
Oral, Tablet, Tablet - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Suppository - Rectal, Intramuscular; Intravenous; Subcutaneous, Rectal, Suppository, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection - Parenteral
Dyspnea
, 5.0 mg, 10.0 mg, 20.0 mg, 40.0 mg, 7.5 mg, 15.0 mg, 30.0 mg, 1.0 mg/mL, 1.5 mg/mL
Oral, Tablet, Tablet - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Suppository - Rectal, Intramuscular; Intravenous; Subcutaneous, Rectal, Suppository, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection - Parenteral
obstetrical analgesia therapy
, 5.0 mg, 10.0 mg, 20.0 mg, 40.0 mg, 7.5 mg, 15.0 mg, 30.0 mg, 1.0 mg/mL, 1.5 mg/mL
Oral, Tablet, Tablet - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Suppository - Rectal, Intramuscular; Intravenous; Subcutaneous, Rectal, Suppository, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection - Parenteral
Perioperative analgesia
, 5.0 mg, 10.0 mg, 20.0 mg, 40.0 mg, 7.5 mg, 15.0 mg, 30.0 mg, 1.0 mg/mL, 1.5 mg/mL
Oral, Tablet, Tablet - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Suppository - Rectal, Intramuscular; Intravenous; Subcutaneous, Rectal, Suppository, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection - Parenteral
Pain
, 5.0 mg, 10.0 mg, 20.0 mg, 40.0 mg, 7.5 mg, 15.0 mg, 30.0 mg, 1.0 mg/mL, 1.5 mg/mL
Oral, Tablet, Tablet - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Suppository - Rectal, Intramuscular; Intravenous; Subcutaneous, Rectal, Suppository, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection - Parenteral
Pain
, 5.0 mg, 10.0 mg, 20.0 mg, 40.0 mg, 7.5 mg, 15.0 mg, 30.0 mg, 1.0 mg/mL, 1.5 mg/mL
Oral, Tablet, Tablet - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Suppository - Rectal, Intramuscular; Intravenous; Subcutaneous, Rectal, Suppository, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection - Parenteral
Warnings
Numorphan has five contra-indications, so it must not be amalgamated while experiencing any of the conditions in the following table.
Numorphan Contraindications
Condition
Risk Level
Notes
Liver Disease
Do Not Combine
Respiratory Insufficiency
Do Not Combine
Hypercarbia
Do Not Combine
Intestinal Pseudo-Obstruction
Do Not Combine
Asthma
Do Not Combine
There are 20 known major drug interactions with Numorphan.
Common Numorphan Drug Interactions
Drug Name
Risk Level
Description
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline
Major
The risk or severity of adverse effects can be increased when Oxymorphone is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.
Astemizole
Major
The metabolism of Astemizole can be decreased when combined with Oxymorphone.
Azelastine
Major
Oxymorphone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Benmoxin
Major
The risk or severity of adverse effects can be increased when Oxymorphone is combined with Benmoxin.
Brofaromine
Major
The risk or severity of adverse effects can be increased when Oxymorphone is combined with Brofaromine.
Numorphan Toxicity & Overdose Risk
An overdose of oxymorphone can cause severe drowsiness, weak muscles, cold and clammy skin, slow heart rate and low blood pressure. It can even lead to difficulty breathing, lack of circulation, and heart failure. The lowest toxic dose in mice has been found to be 172mg/kg.
Numorphan Novel Uses: Which Conditions Have a Clinical Trial Featuring Numorphan?
215 active clinical trials are currently being conducted to evaluate the potential of Numorphan in alleviating Pain, providing analgesia during obstetrical therapy and managing Pain.
Condition
Clinical Trials
Trial Phases
Generalized Anxiety Disorder
181 Actively Recruiting
Not Applicable, Phase 2, Early Phase 1, Phase 4, Phase 1, Phase 3
Perioperative analgesia
0 Actively Recruiting
obstetrical analgesia therapy
1 Actively Recruiting
Not Applicable
Pain
0 Actively Recruiting
Pain
0 Actively Recruiting
Dyspnea
0 Actively Recruiting
Numorphan Reviews: What are patients saying about Numorphan?
5
Patient Review
5/23/2020
Numorphan for Severe Pain
5
Patient Review
2/9/2020
Numorphan for Severe Pain
5
Patient Review
11/1/2019
Numorphan for Additional Agent to Induce General Anesthesia
5
Patient Review
12/2/2021
Numorphan for Severe Pain
5
Patient Review
9/9/2022
Numorphan for Severe Pain
5
Patient Review
10/1/2019
Numorphan for Severe Pain
5
Patient Review
5/23/2020
Numorphan for Severe Pain
5
Patient Review
11/1/2019
Numorphan for Additional Agent to Induce General Anesthesia
5
Patient Review
2/9/2020
Numorphan for Severe Pain
5
Patient Review
10/1/2019
Numorphan for Severe Pain
5
Patient Review
1/10/2018
Numorphan for Pain
5
Patient Review
7/2/2020
Numorphan for Pain
5
Patient Review
12/2/2021
Numorphan for Severe Pain
5
Patient Review
7/2/2020
Numorphan for Pain
5
Patient Review
11/1/2019
Numorphan for Additional Agent to Induce General Anesthesia
5
Patient Review
2/9/2020
Numorphan for Severe Pain
5
Patient Review
10/1/2019
Numorphan for Severe Pain
5
Patient Review
5/23/2020
Numorphan for Severe Pain
5
Patient Review
12/2/2021
Numorphan for Severe Pain
5
Patient Review
1/10/2018
Numorphan for Pain
5
Patient Review
7/2/2020
Numorphan for Pain
5
Patient Review
9/9/2022
Numorphan for Severe Pain
5
Patient Review
1/10/2018
Numorphan for Pain
5
Patient Review
9/9/2022
Numorphan for Severe Pain
5
Patient Review
12/2/2021
Numorphan for Severe Pain
5
Patient Review
10/1/2019
Numorphan for Severe Pain
5
Patient Review
11/1/2019
Numorphan for Additional Agent to Induce General Anesthesia
5
Patient Review
2/9/2020
Numorphan for Severe Pain
5
Patient Review
5/23/2020
Numorphan for Severe Pain
5
Patient Review
1/10/2018
Numorphan for Pain
5
Patient Review
7/2/2020
Numorphan for Pain
5
Patient Review
9/9/2022
Numorphan for Severe Pain
4.7
Patient Review
7/1/2017
Numorphan for Pain
4.7
Patient Review
7/1/2017
Numorphan for Pain
4.7
Patient Review
7/1/2017
Numorphan for Pain
4.7
Patient Review
7/1/2017
Numorphan for Pain
4
Patient Review
10/18/2022
Numorphan for Severe Pain
4
Patient Review
10/18/2022
Numorphan for Severe Pain
4
Patient Review
10/18/2022
Numorphan for Severe Pain
4
Patient Review
10/18/2022
Numorphan for Severe Pain
3.7
Patient Review
7/30/2022
Numorphan for Severe Pain
3.7
Patient Review
7/30/2022
Numorphan for Severe Pain
3.7
Patient Review
7/30/2022
Numorphan for Severe Pain
3.7
Patient Review
7/30/2022
Numorphan for Severe Pain
3.3
Patient Review
6/30/2022
Numorphan for Severe Pain
3.3
Patient Review
6/30/2022
Numorphan for Severe Pain
3.3
Patient Review
6/30/2022
Numorphan for Severe Pain
3.3
Patient Review
6/30/2022
Numorphan for Severe Pain
1.7
Patient Review
12/5/2018
Numorphan for Severe Pain
1.7
Patient Review
12/5/2018
Numorphan for Severe Pain
1.7
Patient Review
12/5/2018
Numorphan for Severe Pain
1.7
Patient Review
12/5/2018
Numorphan for Severe Pain
Patient Q&A Section about numorphan
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.